Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats.

Autor: Nesbitt DJ; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA., Jin DP; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA., Hogan JW; Department of Biostatistics, Brown University, Providence, RI, USA., Yang J; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA., Chen H; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA., Chan PA; Rhode Island Department of Health, Providence, RI, USA., Simon MJ; Rhode Island Commerce Corporation, Providence, RI, USA., Vargas M; Rhode Island Commerce Corporation, Providence, RI, USA., King E; Rhode Island Department of Health, Providence, RI, USA.; Rhode Island State Health Laboratory, Providence, RI, USA., Huard RC; Rhode Island Department of Health, Providence, RI, USA.; Rhode Island State Health Laboratory, Providence, RI, USA., Bandy U; Rhode Island Department of Health, Providence, RI, USA., Hillyer CD; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA., Luchsinger LL; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA. lluchsinger@nybc.org.
Jazyk: angličtina
Zdroj: BMC infectious diseases [BMC Infect Dis] 2021 Aug 25; Vol. 21 (1), pp. 871. Date of Electronic Publication: 2021 Aug 25.
DOI: 10.1186/s12879-021-06438-4
Abstrakt: Background: Epidemic projections and public health policies addressing Coronavirus disease (COVID)-19 have been implemented without data reporting on the seroconversion of the population since scalable antibody testing has only recently become available.
Methods: We measured the percentage of severe acute respiratory syndrome- Coronavirus-2 (SARS-CoV-2) seropositive individuals from 2008 blood donors drawn in the state of Rhode Island (RI). We utilized multiple antibody testing platforms, including lateral flow immunoassays (LFAs), enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). To estimate seroprevalence, we utilized the Bayesian statistical method to adjust for sensitivity and specificity of the commercial tests used.
Results: We report than an estimated seropositive rate of RI blood donors of approximately 0.6% existed in April-May of 2020. Daily new case rates peaked in RI in late April 2020. We found HTSAs and LFAs were positively correlated with ELISA assays to detect antibodies specific to SARS-CoV-2 in blood donors.
Conclusions: These data imply that seroconversion, and thus infection, is likely not widespread within this population. We conclude that IgG LFAs and HTSAs are suitable to conduct seroprevalence assays in random populations. More studies will be needed using validated serological tests to improve the precision and report the kinetic progression of seroprevalence estimates.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje